Publications by authors named "W Curry"
Context: Chimeric antigen receptor (CAR) T cell therapy is an exciting modality of immunotherapy that has revolutionized the treatment of hematologic malignancies. However, translating this success to malignant gliomas such as glioblastoma (GBM) and diffuse midline glioma (DMG) remains a formidable challenge due to multiple biologic, anatomic, and immunologic factors. Despite these hurdles, a number of clinical trials deployed over the last decade have increased optimism for the potential of CAR T cell therapy in glioma treatment.
View Article and Find Full Text PDFPurpose: The literature on skull base chondrosarcoma (CHS) is scarce. We report outcomes for pediatric and young patients ≤22 years with base of skull CHSs treated with proton-based radiation therapy (PBRT).
Methods And Materials: We retrospectively reviewed all patients treated with PBRT between 1981 and 2023.
Immunotherapy represents a transformative shift in cancer treatment. Among myriad immune-based approaches, chimeric antigen receptor (CAR) T-cell therapy has shown promising results in treating hematological malignancies. Despite aggressive treatment options, the prognosis for patients with malignant brain tumors remains poor.
View Article and Find Full Text PDFArticle Synopsis
- Mutations in IDH1 and IDH2 genes play important roles in diagnosing and predicting outcomes in diffuse gliomas, particularly regarding their effects on immune cell populations within tumors.
- This study used RNA sequencing and preclinical models to analyze the impact of IDH mutations on myeloid cells in glioma specimens, revealing that IDH-mutant tumors have fewer suppressive myeloid cells compared to IDH-wild-type tumors.
- The research suggests that targeting the myeloid cell populations affected by mutant IDH could be a potential therapeutic approach for treating high-grade gliomas.